SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2

Completed · Phase 3 · Has a placebo group

Conditions studied: Type II Diabetes Mellitus

In brief

In Protocol 2, the investigators will determine the role of pancreatic hormones (increase in plasma glucagon and decrease in plasma insulin concentration) in the stimulation of EGP following SGLT2 inhibition.

Key facts

Study ID

NCT02592421

Run by

The University of Texas Health Science Center at San Antonio

People needed

30

Starts

2015-10-23

Expected to finish

2019-10-31

Last updated by the study team

2020-09-17

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• T2DM subjects
• 18 - 70 yrs old
• BMI = 25-45 kg/m2
• Must be on a stable dose (more than 3 months) of monotherapy or combination therapy with metformin and/or a sulfonylurea
• HbA1c <10.0%
• Stable body weight (± 3 lbs) over preceding 3 months
• Do not participate in excessively heavy exercise

You may not qualify if…

• Subjects taking drugs known to affect glucose metabolism (other than metformin and sulfonylurea)
• Individuals with evidence of proliferative diabetic retinopathy, plasma creatinine >1.4 females or >1.5 males, or 24-hour urine albumin excretion > 300 mg

Where it is running

• University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.